Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab

Key Points

• Poor prognosis is associated with non-thyroidal illness syndrome during treatment with atezolizumab and bevacizumab.
• Thyroid dysfunction, detected during therapy, correlates with systemic deterioration and highlights patient survival risk.
• Assessment of thyroid function may aid in determining which patients are at higher risk of poor outcomes.
• Routine monitoring highlights the potential for better risk stratification in hepatocellular carcinoma treatment.